Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein
about
Statins for primary prevention of venous thromboembolismHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisStatins for the primary prevention of cardiovascular diseaseStatins for primary prevention of venous thromboembolismRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveTrends in Statin Use in Seniors 1999 to 2013: Time Series AnalysisAll cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.American Diabetes Association indications for statins in diabetes: is there evidence?Atherosclerosis: A Link Between Lipid Intake and Protein Tyrosine NitrationMy patient has an elevated hs-CRP. What does this mean? What should I do now?The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndromeEstimating treatment effects for individual patients based on the results of randomised clinical trials.On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: aNew evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor.Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.Efficacy and safety of rosuvastatin in the management of dyslipidemiaInflammation, C-reactive protein, and atherothrombosis.A randomized trial of rosuvastatin in the prevention of venous thromboembolism.Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: The Heart and Soul Study.Biomarkers of atherosclerosis: clinical applicationsThe effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in manThe Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.C-reactive protein, statins and the risk of vascular events: a better understanding.Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque.Role of tissue factor in atherothrombosis.The evolution or revolution of statin therapy in primary prevention: where do we go from here?Cardiovascular risk in the rheumatic disease patient undergoing orthopedic surgery.Complete blood count risk score and its components, including RDW, are associated with mortality in the JUPITER trial.Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.CRP is a novel ligand for the oxidized LDL receptor LOX-1.Highly sensitive C-reactive protein and male gender are independently related to the severity of coronary disease in patients with metabolic syndrome and an acute coronary event.Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function.Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH.
P2860
Q24187238-4C7857EB-BB55-4E91-A411-C9A94C516AB2Q24194514-30FF6565-BFA1-4712-8A00-673D051CC814Q24201513-A6A4CC53-9E10-4643-9BB5-99688AAA181CQ24204040-29749ABB-1E4E-458E-9EA0-8DA316FEA319Q24594814-103EF509-D96D-42BE-BF00-880C90733E22Q28552707-BF011D2F-1524-4C11-91B0-B1C6C6A30F52Q31101617-B03A2D51-4F4D-482C-A3DD-BF484B5F0DC1Q33610712-C5BF4C8D-C368-4723-807B-D871C3DCE6C9Q33649712-CC823AB7-CCD0-4023-845B-4D4C92995466Q34481383-1F97BB85-48C8-4138-AA81-505D532AF8CFQ35059481-4E7DD920-3058-4083-A920-68BA25400B84Q35252544-99C25BE9-0693-4D20-B94B-A2E9CB464497Q35917224-771B007E-6AB1-4044-AE79-D67B556C0186Q36897456-3805EB63-42D4-48AA-A481-6DEFC7F01ED5Q37031309-6A4F00E2-0E12-4F04-AC53-62E0EC8FBAB8Q37167517-F06CF3E2-5113-4554-9EA8-6DFD9CCEDE2EQ37232611-15B45810-6D9E-4488-9770-DB8945A285D3Q37262627-D138561B-66A3-4E01-A8F9-1D0D80528BFAQ37279061-0BB159F6-7D3D-4211-990C-E913F99A61D9Q37307999-9B16DF30-617C-4A8C-BC22-C5748A2E04FEQ37479070-57D510FC-6A31-4376-8F95-D39996ACD094Q37491763-B148B1F1-7082-420B-A57E-BF4B5EC9D6E6Q37906353-7EC96FCF-5308-423E-8583-2E764B4898F9Q37996577-8BD2E854-A4B0-4AE4-B9ED-789E500234D2Q38034092-4E57E4EB-8449-4DE9-A783-1FA8F6CEDF71Q38072612-1E498E72-1CB9-4A67-8020-925AE2DD9C2DQ38124279-D902AFE2-566A-483A-8AB2-C819B1D61B67Q38451132-3A13D0CB-BA29-45C1-92FD-BD05D0302DACQ38471162-1E222363-3DAF-46B0-BBD5-6A883818393EQ39878373-35BB7075-8CC3-45F6-A60E-08273AFEAD9BQ43140024-F44FF858-3152-4931-AB77-A4D59537F9D8Q46751641-5E4897E7-680A-4C91-87FF-D56F3DA4936AQ55358328-D4173E43-C277-44AA-9338-19EA74C28CB9
P2860
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Baseline characteristics of pa ...... sensitivity C-reactive protein
@en
type
label
Baseline characteristics of pa ...... sensitivity C-reactive protein
@en
prefLabel
Baseline characteristics of pa ...... sensitivity C-reactive protein
@en
P2093
P50
P921
P1476
Baseline characteristics of pa ...... sensitivity C-reactive protein
@en
P2093
Alberto J Lorenzatti
Antonio M Gotto
Francisco A H Fonseca
JUPITER Trial Study Group
James Shepherd
James T Willerson
John J P Kastelein
Nardev S Khurmi
Paul M Ridker
Robert J Glynn
P304
P356
10.1016/J.AMJCARD.2007.09.072
P407
P577
2007-10-24T00:00:00Z